Luo G, Zhang Y, Etxeberria J, Arnold M, Cai X, Hao Y, Zou H. Projections of Lung Cancer Incidence by 2035 in 40 Countries Worldwide: Population-Based Study. JMIR Public Health Surveill. 2023;9:e43651.
He S, Xia C, Li H, Cao M, Yang F, Yan X, Zhang S, Teng Y, Li Q, Chen W. Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors. Sci China Life Sci. 2024;67(1):122–31.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Holland JC, Bultz BD. The NCCN guideline for distress management: a case for making distress the sixth vital sign. J Natl Compr Canc Netw. 2007;5(1):3–7.
Yan X, Chen X, Li M, Zhang P. Prevalence and risk factors of anxiety and depression in Chinese patients with lung cancer: a cross-sectional study. Cancer Manag Res. 2019;11:4347–56.
Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10(4):1367–401.
Keefe DMK, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol. 2012;9(2):98–109.
Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645–53.
Akin S, Can G, Aydiner A, Ozdilli K, Durna Z. Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs. 2010;14(5):400–9.
Prapa P, Papathanasiou IV, Bakalis V, Malli F, Papagiannis D, Fradelos EC. Quality of life and psychological distress of lung cancer patients undergoing chemotherapy. World J Oncol. 2021;12(2–3):61–6.
Luo Y, Mao D, Zhang L, Yang Z, Miao J, Zhang L. Identification of symptom clusters and sentinel symptoms during the first cycle of chemotherapy in patients with lung cancer. Support Care Cancer. 2024;32(6):385.
Morrison EJ, Novotny PJ, Sloan JA, Yang P, Patten CA, Ruddy KJ, Clark MM. Emotional problems, quality of life, and symptom burden in patients with lung cancer. Clin Lung Cancer. 2017;18(5):497–503.
Wang X, Ma X, Yang M, Wang Y, Xie Y, Hou W, Zhang Y. Proportion and related factors of depression and anxiety for inpatients with lung cancer in China: a hospital-based cross-sectional study. Support Care Cancer. 2022;30(6):5539–49.
Akechi T, Okuyama T, Uchida M, Nakaguchi T, Sugano K, Kubota Y, Ito Y, Kizawa Y, Komatsu H. Clinical indicators of depression among ambulatory cancer patients undergoing chemotherapy. Jpn J Clin Oncol. 2012;42(12):1175–80.
Wang D, Fu J. Symptom clusters and quality of life in China patients with lung cancer undergoing chemotherapy. Afr Health Sci. 2014;14(1):49–55.
Chen K, Yang D, Li F, Gao L, Tian Y, Xu B, Xu X, Xu Q, Cao J. Changes in the symptom clusters of elderly patients with lung cancer over the course of postoperative rehabilitation and their correlation with frailty and quality of life: a longitudinal study. Eur J Oncol Nurs. 2023;67:102388.
Kwekkeboom KL. Cancer symptom cluster management. Semin Oncol Nurs. 2016;32(4):373–82.
Shahedah KK, How SH, Jamalludin AR, Mohd Faiz MT, Kuan YC, Ong CK. Depressive symptoms in newly diagnosed lung carcinoma: prevalence and associated risk factors. Tuberc Respir Dis (Seoul). 2019;82(3):217–26.
Wu XN, Su D, Li HP, Wang WL, Wu WQ, Yang YJ, Yu FL, Zhang JP. Relationship between the depression status of patients with resectable non-small cell lung cancer and their family members in China. Eur J Oncol Nurs. 2013;17(5):668–72.
Riedl D, Schüßler G. Factors associated with and risk factors for depression in cancer patients – a systematic literature review. Transl Oncol. 2022;16:101328.
Lee Y, Lin PY, Lin MC, Wang CC, Lu HI, Chen YC, Chong MY, Hung CF. Morbidity and associated factors of depressive disorder in patients with lung cancer. Cancer Manag Res. 2019;11:7587–96.
Stommel M, Kurtz ME, Kurtz JC, Given CW, Given BA. A longitudinal analysis of the course of depressive symptomatology in geriatric patients with cancer of the breast, colon, lung, or prostate. Health Psychol. 2004;23(6):564–73.
Chang WP, Lin CC. Changes in the sleep-wake rhythm, sleep quality, mood, and quality of life of patients receiving treatment for lung cancer: a longitudinal study. Chronobiol Int. 2017;34(4):451–61.
Andersen BL, McElroy JP, Carbone DP, Presley CJ, Smith RM, Shields PG, Brock GN. Psychological symptom trajectories and non-small cell lung cancer survival: a joint model analysis. Psychosom Med. 2022;84(2):215–23.
Kuehne N, Hueniken K, Xu M, Shakik S, Vedadi A, Pinto D, Brown MC, Bradbury PA, Shepherd FA, Sacher AG, et al. Longitudinal assessment of health utility scores, symptoms and toxicities in patients with small cell lung cancer using real world Data. Clin Lung Cancer. 2022;23(2):e154–64.
Ram N, Grimm KJ. Growth mixture modeling: a method for identifying differences in longitudinal change among unobserved groups. Int J Behav Dev. 2009;33(6):565–76.
Shader TM, Beauchaine TP. A Monte Carlo evaluation of growth mixture modeling. Dev Psychopathol. 2022;34(4):1604–17.
Xie Y, Ma M, Wang W. Trajectories of depressive symptoms and their predictors in Chinese older population: growth mixture model. BMC Geriatr. 2023;23(1):372.
Association AP. Diagnostic and statistical manual of mental disorders. 2013Fifth Edition Arlington. Arlington, VA: VA American Psychiatric Association; 2013.
Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. 2001;16(9):606–13.
Hinz A, Mehnert A, Kocalevent R-D, Brähler E, Forkmann T, Singer S, Schulte T. Assessment of depression severity with the PHQ-9 in cancer patients and in the general population. BMC Psychiatry. 2016;16(1):22.
Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129–38.
Wang XS, Mendoza TR, Gao S-Z, Cleeland CS. The chinese version of the Brief Pain Inventory (BPI-C): its development and use in a study of cancer pain. PAIN. 1996;67(2-3):407–16.
Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186–96.
Wang XS, Hao XS, Wang Y, Guo H, Jiang YQ, Mendoza TR, Cleeland CS. Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-C). J Pain Symptom Manage. 2004;27(4):322–32.
Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48(6):555–60.
Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res. 2003;55(3):263–7.
Qiu H, Ren W, Yang Y, Zhu X, Mao G, Mao S, Lin Y, Shen S, Li C, Shi H, et al. Effects of cognitive behavioral therapy for depression on improving insomnia and quality of life in Chinese women with breast cancer: results of a randomized, controlled, multicenter trial. Neuropsychiatr Dis Treat. 2018;14:2665–73.
Zhang Y, Tan X, Li W, Wang H, Sun H, Liu T, Zhang J, Zhang B, Yang Y. Self-perceived pain in Chinese patients with cancer. Front Psychol. 2019;10:1994.
Luo J, Liu R, Luo Y, Fang Q, Liu S, Yang Z, Miao J, Zhang L. The high burden of symptoms associated with cognitive impairment in lung cancer patients: a latent class analysis. Asia Pac J Oncol Nurs. 2023;10(4):100200.
Jo B, Findling RL, Wang CP, Hastie TJ, Youngstrom EA, Arnold LE, Fristad MA, Horwitz SM. Targeted use of growth mixture modeling: a learning perspective. Stat Med. 2017;36(4):671–86.
van der Nest G, Lima Passos V, Candel M, van Breukelen GJP. An overview of mixture modelling for latent evolutions in longitudinal data: modelling approaches, fit statistics and software. Adv Life Course Res. 2020;43:100323.
Aflaki K, Vigod S, Ray JG. Part II: A step-by-step guide to latent class analysis. J Clin Epidemiol. 2023;159:348–51.
Kurtz ME, Kurtz JC, Stommel M, Given CW, Given B. Predictors of depressive symptomatology of geriatric patients with lung cancer-a longitudinal analysis. Psychooncology. 2002;11(1):12–22.
Boyes AW, Girgis A, D’Este CA, Zucca AC, Lecathelinais C, Carey ML. Prevalence and predictors of the short-term trajectory of anxiety and depression in the first year after a cancer diagnosis: a population-based longitudinal study. J Clin Oncol. 2013;31(21):2724–9.
McFarland DC, Miller AH, Nelson C. A longitudinal analysis of inflammation and depression in patients with metastatic lung cancer: associations with survival. Biol Res Nurs. 2021;23(3):301–10.
Tian X, Jin Y, Chen H, Tang L, Jiménez-Herrera MF. Relationships among social support, coping style, perceived stress, and psychological distress in chinese lung cancer patients. Asia Pac J Oncol Nurs. 2021;8(2):172–9.
Chau YF, Zhou H, Chen B, Ren H, Ma Z, Zhang X, Duan J. Screening for depression and anxiety in lung cancer patients: a real-world study using GAD-7 and HADS. Thorac Cancer. 2024;15(13):1041–9.
Park S, Kang CH, Hwang Y, Seong YW, Lee HJ, Park IK, Kim YT. Risk factors for postoperative anxiety and depression after surgical treatment for lung cancer †. Eur J Cardiothorac Surg. 2015;49(1):e16–21.
Riemann D, Krone LB, Wulff K, Nissen C. Sleep, insomnia, and depression. Neuropsychopharmacology. 2020;45(1):74–89.
Lin SY, Stevens MB. The symptom cluster-based approach to individualize patient-centered treatment for major depression. J Am Board Fam Med. 2014;27(1):151–9.
Ji YB, Bo CL, Xue XJ, Weng EM, Gao GC, Dai BB, Ding KW, Xu CP. Association of inflammatory cytokines with the symptom cluster of pain, fatigue, depression, and sleep disturbance in Chinese patients with cancer. J Pain Symptom Manage. 2017;54(6):843–52.
Sullivan DR, Forsberg CW, Ganzini L, Au DH, Gould MK, Provenzale D, Slatore CG. Longitudinal changes in depression symptoms and survival among patients with lung cancer: a National Cohort Assessment. J Clin Oncol. 2016;34(33):3984–91.
Ota A, Kawada K, Tsutsumi A, Yatsuya H. Cross-sectional association between working and depression prevalence in cancer survivors: a literature review. Environ Occup Health Pract. 2020;2(1):2020-0006-RA. https://www.jstage.jst.go.jp/article/eohp/2/1/2_2020-0006-RA/_article/-char/ja/.
Andersen BL, Valentine TR, Lo SB, Carbone DP, Presley CJ, Shields PG. Newly diagnosed patients with advanced non-small cell lung cancer: a clinical description of those with moderate to severe depressive symptoms. Lung Cancer. 2020;145:195–204.
Lee SA, Ju YJ, Han K-T, Choi JW, Yoon HJ, Park E-C. The association between loss of work ability and depression: a focus on employment status. Int Arch Occup Environ Health. 2017;90(1):109–16.
Lieb M, Wünsch A, Schieber K, Bergelt C, Faller H, Geiser F, Goerling U, Hönig K, Hornemann B, Maatouk I, et al. Return to work after cancer: improved mental health in working cancer survivors. Psychooncology. 2022;31(6):893–901.
Cohee AA, Kroenke K, Vachon E, Wu J, Tu W, Johns SA. Predictors of depression outcomes in adults with cancer: a 12 month longitudinal study. J Psychosom Res. 2020;136:110169.
Chan RJ, Gordon LG, Tan CJ, Chan A, Bradford NK, Yates P, Agbejule OA, Miaskowski C. Relationships between financial toxicity and symptom burden in cancer survivors: a systematic review. J Pain Symptom Manage. 2019;57(3):646-660.e641.
Cai Y, Chen W, Wang X, Xia X, Cui X, Wu S, Li J. Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during 2008–2017. Chin J Cancer Res. 2021;33(5):627–36.
Yin X, Xu Y, Man X, Liu L, Jiang Y, Zhao L, Cheng W. Direct costs of both inpatient and outpatient care for all type cancers: the evidence from Beijing. China Cancer Med. 2019;8(6):3250–60.
Boulanger M, Mitchell C, Zhong J, Hsu M. Financial toxicity in lung cancer. Front Oncol. 2022;12:1004102.
Add Comment